The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is set to grow from $3.7 billion in 2016 to around $16.1 billion by 2026, according to research and consulting firm GlobalData. This represents an impressive compound annual growth rate of 15.7 percent.


Cardiac nuclear myocardial perfusion imaging (MPI) has been a mature area of imaging for years, but has recently started a transformation with new technologies, protocols and applications. This is partly due to the availability of technologies, concerns about dose, competition, reimbursement and concerns over isotope availability. 


Gecko Biomedical announced it has received CE Mark approval for its Setalum Sealant, allowing the company to market its technology in Europe.

September 18, 2017 — Corindus Vascular Robotics Inc. announced first patient enrollment in the PRECISION GRX Registry, a post-market study to continue market surveillance of the company's second-generation CorPath GRX System.

Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating the efficacy of Philips Spectranetics' Stellarex .035-inch drug-coated balloon (DCB) for peripheral arterial disease (PAD) in comparison to uncoated balloon angioplasty. Marianne Brodmann, M.D., of the Medical University of Graz in Austria, presented the data as a late-breaking trial at the Vascular Interventional Advances (VIVA 17) Annual Conference, Sept. 11-14 in Las Vegas.

September 18, 2017 – Claret Medical announced publication of a new study in the Journal of the American College of Cardiology (JACC): Cardiovascular Interventions that underscores the role of the Sentinel Cerebral Protection System (CPS) in significantly reducing the early occurrence of stroke associated with

Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its QMAPP hemodynamic monitoring system.

Hitachi Healthcare Americas Inc. announced it has attained U.S. Food and Drug Administration (FDA) 510(k) clearance to market its Supria True64 computed tomography (CT) system.

Subscribe Now